- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03147898
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
April 21, 2022 updated by: Sanofi
Characterization of Humoral and Cell-Mediated Immune Responses Following a Booster Dose of Pertussis Vaccine
This is an observational study designed to describe the immune profile of toddlers and preschoolers with acellular priming after receiving a booster dose of pertussis vaccine.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
90
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 4 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Healthy subjects aged 15 to 59 months
Description
Inclusion Criteria:
An individual must fulfill all of the following criteria in order to be eligible for study enrollment:
Toddler Cohort:
- Aged 15 to 24 months on the day of (V01)
- Has received 3 doses of a licensed pertussis-containing vaccine for a priming series during infancy in accordance with the recommendations of the NIP or his / her primary care physician
- Has written documentation (e.g., immunization record, physician's certificate, vaccination unit registry) available to verify the receipt of 3 doses of a licensed pertussis-containing infant vaccines as per national immunization schedule
- ICF has been signed and dated by the subject's parent(s) / legally acceptable representative(s) and, if required, an independent witness, in accordance with local regulations
- Planned receipt of routine pertussis booster vaccine, preferably, on same date as, and no more than 2 days following, V01
- Participant and parent / legally acceptable representative are able to attend all scheduled visits and to comply with all study procedures
Preschooler Cohort:
- Aged 48 to 59 months on the date of V01
- Has received 4 doses of pertussis-containing combination vaccines as per national immunization schedule
Exclusion Criteria:
An individual fulfilling any of the following criteria is to be excluded from study enrollment:
- Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine in the 4 weeks preceding the study or planned receipt of any vaccine (other than a booster pertussis vaccine) between V01 and V03a
- Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months
- Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within the preceding 3 months
- History of clinically- or laboratory-confirmed pertussis as per the WHO recommended case definition
- Bleeding disorder, verbal report of thrombocytopenia, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating venipuncture, in the opinion of the investigator
- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (in the opinion of the investigator) or febrile illness (temperature ≥ 38.0°C) at physical examination on V01 of the study. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Receipt of oral or injected antibiotics therapy within the 72 hours preceding the first blood draw. (Topical antibiotics and antibiotic drops are not included in this exclusion criterion).
- Identified as a natural or adopted child of the Investigator or an employee with direct involvement in the proposed study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Group 1: Toddlers
Non-intervention observational study.
Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
|
Group 2: Toddlers
Non-intervention observational study.
Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
|
Group 3: Preschooler
Non-intervention observational study.
Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
|
Group 4: Preschooler
Non-intervention observational study.
Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti Pertussis antibody concentrations pre and post vaccination
Time Frame: Day 30 post vaccination
|
The change in antibody concentrations will be measured from pre to post vaccination
|
Day 30 post vaccination
|
Change in magnitude of T-cell responses to pertussis-containing combination vaccines over time
Time Frame: Day 30 post vaccination
|
The change in cell mediated immune responses will be evaluated from pre to post vaccination
|
Day 30 post vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Officer, Sanofi Pasteur Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2017
Primary Completion (Actual)
July 9, 2018
Study Completion (Actual)
July 9, 2018
Study Registration Dates
First Submitted
May 8, 2017
First Submitted That Met QC Criteria
May 9, 2017
First Posted (Actual)
May 10, 2017
Study Record Updates
Last Update Posted (Actual)
April 25, 2022
Last Update Submitted That Met QC Criteria
April 21, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NGB00001
- U1111 1183 5461 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsNot yet recruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
University of VirginiaUnknownCarriage of Bordetella PertussisUnited States